The proprietary MyGenera™ platform is at the core of Biogenera’s innovation. This revolutionary biotechnology enables the rapid and precise identification of new “anti-gene” drug candidates, specifically targeting a single gene identified as the cause of a particular disease, offering a pioneering approach to treatment. Unlike traditional “antisense” approaches that aim to inhibit RNA translation, MyGenera™ acts directly at the source—the gene—by blocking the transcription of DNA into RNA, known as the anti-gene approach.

At the core of the process is a proprietary bioinformatic approach that enables the rapid identification of a limited number of PNA-based anti-gene oligonucleotides (Ag-PNA) capable of specifically blocking the target gene and meeting predefined selection criteria. The platform allows for fast and accurate evaluation, ensuring that only compounds with the highest therapeutic potential, specificity, and safety proceed through the development process. The subsequent refinement involves further molecular and cellular pharmacodynamic evaluations, following increasingly stringent criteria to select the optimal Ag-PNA (the drug candidate).